Document is current
Any future updates will be listed below
-
Authors
Sharma, Ashish https://orcid.org/0000-0002-8550-9791
Khanani, Arshad M.
Eichenbaum, David
Boyer, David https://orcid.org/0000-0001-9219-1614
Shaer, Alexander
Ortiz, Trisha
Sulahria, Humza https://orcid.org/0000-0002-1779-2097
Flores, Allyza
Regillo, Carl https://orcid.org/0000-0001-8260-9925
,
Kuppermann, Baruch D.
Loewenstein, Anat
Bandello, Francesco
Querques, Giuseppe
Ueda-Consolvo, Tomoko
Ishida, Masaaki
Nakamura, Tomoko
Hayashi, Atsushi
Tsuboi, Kotaro
Kumar, Nilesh
Parachuri, Nikulaa
Sheth, Jay
Mishra, Chitaranjan
Chakraborty, Debdulal
Banker, Alay
Rezaei, Kourous A.
Kaiser, Peter K.
Holz, Frank G.
Sivaprasad, Sobha
Özdek, Şengül
Laurent, Kodjikian
Bilgic, Alper
Lanzetta, Paolo
Sarao, Valentina
Baumal, Caroline
Holekamp, Nancy
Sakamoto, Taiji
Tufail, Adnan
Yannuzzi, Nicolas
Sridhar, Jayanth
Corradetti, Giulia
Rachitskaya, Aleksandra
Peto, Tunde
Wintergerst, Maximilian W. M.
Parolini, Barbara
Nguyen, Quan Dong
Do, Diana V.
Keane, Pearse A.
Hassan, Tarek
Grewal, Dilraj S.
March, Francesc
Spitzer, Martin S.
Falavarjani, Khalil G.
Zinkernagel, Martin S.
Lee, Christopher Seungkyu
Kim, Judy E.
Woo, Se Joon
Nicholson, Luke
Vazquez-Alfageme, Clara
Wakabayashi, Taku
- License Information
-
More Information
Article History
Received: 6 January 2026
Revised: 2 February 2026
Accepted: 10 February 2026
First Online: 2 March 2026
Competing interests
: Ashish Sharma: Consultant for Oculis, Novartis, Allergan, Bayer, Lupin, Intas, Ajanta and Sun Pharma Speaker fee MS Pharma, Abdi İbrahim İlaç San. ve Tic, Samil Pharma, Roche. Arshad M Khanani: Consultant: Abbvie, ADARx Pharmaceuticals, Adverum, Alcon, Alkeus, Allgenesis, Amgen, Annexin, Annexon, Apellis Pharmaceuticals, Ashvattha, Therapeutics, Astellas, Aviceda Therapeutics, Beacon Therapeutics, Boehringer Ingelheim, Clearside Biomedical, Complement Therapeutics, 4DMT, Entarada, Exegenesis, EyePoint Pharmaceuticals, Fronterra Therapeutics, Genentech, Harrow, i-Lumen Scientific, InFocus, Iveric Bio, Janssen Pharmaceuticals, Kriya Therapeutics, Kyowa Kirin, Lexitas, Merit, Neurotech, Nanoscope, Novartis, Ocugen, Ocular Therapeutix, Oculis, Ollin, Opthea, Opus Genetics, Perfuse, Recens Medical, Regeneron Pharmaceuticals, Regenxbio, Revive, RevOpsis, Roche, Samsung, Sanofi, Stealth BioTherapeutics, Sun Pharma, Surrozen, Thea Pharma, Therini, Unity Biotechnology, Vanotech, Vial, ZipBio. Research support: Aviceda, Adverum, Alexion, Annexon, Astellas, Aviceda Therapeutics, Biojiva Complement Therapeutics, 4DMT, Eyepoint Pharmaceuticals, Exegenesis, Genentech, Gyroscope Therapeutics, Iveric Bio, Janssen, Kyowa Kirin, Ocular, Ollin, Therapeutix, Regenxbio, Roche, Sanofi, Vanotech. Stock options: Ashvattha, Aviceda Therapeutics, Oculis, Ollin, PolyPhotonix, Recens Medical, Perfuse, RevOpsis, Vial, ZipBio. Board of Directors: Oculis. : Consultant: Alimera, Allergan, Apellis, Bausch + Lomb, Dutch Ophthalmic, EyePoint, Genentech, Inc., Gyroscope, Iveric Bio, KKR, Kodiak, Novartis, Recens Medical, Regeneron, Regenxbio, Vial; Equity/Stockholder: Boston Image Reading Center, Clearside, Hemera, Network Eye, US Retina; Founder: Network Eye; Investigator: Alkahest, Annexon, AsclepiX, Bayer, Chengdu, EyePoint, Gemini, Genentech, Inc., Gyroscope, Ionis, Iveric Bio, Kodiak, Mylan, NGM, Novartis, Ocular Therapeutix, Ophthea, RecensMedical, Regeneron, Regenxbio, Unity; Speaker: Allergan, Apellis, Bayer, Dutch Ophthalmic, EyePoint, Genentech, Inc., Novartis. David Boyer: David Boyer, MD, has disclosed that he has received grants for clinical research and educational activities from Novartis, Alcon, Genentech, Pfizer/OSI, and Allergan. Dr. Boyer has also disclosed that he has served as an advisor or consultant to Novartis, Alcon, Genentech, Pfizer/OSI, and Allergan. Alexander Shaer: None. Trisha Ortiz: None. Humza Sulahria: None. Allyza Flores: None. Carl Regillo: Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, Aviceda, Bausch and Lomb, Chengdu Kanghong, Cognition, EyePoint, Genentech, Janssen, Kodiak, Lineage, Kyoto Drug Development, Merck, NGM, Novartis, Ocugen, Ocuterra, Opus Genetics, Opthea, Ray, RegenXBio, Stealth, Thea, Zeiss, ZipBio; Research grant support: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Gyroscope, Iveric, Janssen, Kodiak, Lineage, NGM, Notal, Novartis, Ocugen, Ocuterra, Opthea, Regeneron, RegenXBio.
